Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in TumorsMOLECULAR CANCER THERAPEUTICSIF5.52023-02-1014OA
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibodyONCOIMMUNOLOGYIF6.32022-11-0415OA